Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized end-of-Phase 2 discussions with the U.S. Food and Drug Administration (FDA) and next steps for its Phase 3 pivotal registration program for bremelanotide, its product in development as a novel treatment for female sexual dysfunction (FSD). Palatin will hold a conference call and live audio webcast later today.

End-of-Phase 2 Meeting with FDA on Bremelanotide for FSD
In the end-of-Phase 2 meeting with FDA, Palatin reached preliminary agreement on key aspects of the Phase 3 pivotal registration studies, including:

  • FSD patient population
  • Primary and key secondary efficacy endpoints
  • Study design
  • Dose selection
  • Safety monitoring
  • In addition, the FDA agreed with Palatin's position that the blood pressure and heart rate signals of bremelanotide had been adequately characterized during the Phase 2 program. The FDA also agreed with the proposed Phase 3 blood pressure monitoring program, which will consist of standardized methods for in-clinic assessment of blood pressure.

    "We view our positive meeting with the FDA as a major milestone in the development of bremelanotide for FSD. We are pleased to have concurrence from the FDA on the design and selection of efficacy endpoints of our Phase 3 clinical studies," stated Carl Spana, Ph.D., President and CEO of Palatin. "We are also pleased with the FDA's concurrence that the blood pressure monitoring program for our Phase 3 clinical studies only includes standardized methods for in-clinic assessment of blood pressure. We look forward to advancing bremelanotide for FSD towards a suc
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    3. Palatin Technologies To Present At The 25th Annual ROTH Conference
    4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
    (Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
    (Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
    (Date:7/23/2014)... Emirates (UAE) (PRWEB) July 23, 2014 ... recently announced that its biobanking project, Provia ... Ph.D. to its growing Advisory Board. Scott Wolf ... pleased to have Dr. Vaught onboard with Provia’s ever-expanding ... and expertise that Provia’s management team brings to this ...
    Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4
    ... - Company to Host Conference Call at 4:30 p.m. ET ... PCYC ) today reported financial results for its fourth ... for the fourth quarter of,fiscal 2008 was $4.6 million, or ... or $0.27 per share, for the fourth quarter of fiscal ...
    ... is accelerating improvements for converting plant biomass into biofuelas ... needs, reports Eddy Rubin, Director of the U.S. Department ... August 14 edition of the journal Nature . ... a path forward for how emerging genomic technologies will ...
    ... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced that ... leading proxy advisory firms, have,recommended that SGX stockholders vote ... LLY ) at the SGX Special Stockholders Meeting,scheduled ... The Board of Directors of SGX unanimously recommends ...
    Cached Biology Technology:Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 2DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 3DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature 4SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 2SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 3SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms 4
    (Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
    (Date:7/24/2014)... Citing many sobering examples of how wildlife loss leads ... article co-authored by Wildlife Conservation Society (WCS) Health ... Christopher Golden, calls for an interdisciplinary approach to tackle ... directly supports about 15% of the world,s people and ... world,s poor. It should come as no surprise that ...
    (Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
    Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
    ... influenza caused widespread death and illness in 1918, 1957, 1968 ... time of these pandemics finds that each of them was ... study,s authors--Jeffrey Shaman of Columbia University,s Mailman School of Public ... Healthnote that the La Nia pattern is known to alter ...
    ... new varieties of corn with a higher yield faster than ... Germany, and other institutions are relying on a trick: early ... chemical and genetic makeup, as well as on new statistical ... authoritative journal Nature Genetics on Sunday evening, Jan. ...
    ... proteins have characteristic ways of "walking," which (also like human ... have discovered the unique "drunken sailor" gait of dynein, a ... in the body and whose malfunction has been associated with ... The research, which was led by Samara Reck-Peterson ...
    Cached Biology News:Does the La Niña weather pattern lead to flu pandemics? 2Good parents are predictable -- at least when it comes to corn 2Good parents are predictable -- at least when it comes to corn 3Good parents are predictable -- at least when it comes to corn 4Walk this way: Scientists and MBL physiology students describe how a motor protein 'steps out' 2
    Porcine IFN-gamma ELISpot Development Module...
    ... 5 ml of DETACHaBEAD 19 polyclonal ... CD19 (Pan B). B cells ... and released with DETACHaBEAD CD19 are ... suitable for applications such as culturing ...
    This Malachite Green Phosphate Detection Kit...
    5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
    Biology Products: